The c-Jun NH2-terminal kinase (JNK) signaling pathway participates in many physiological functions. In the current study we reported the cloning and characterization of five novel JNK2 transcript variants, which were designated as JNK2α3, JNK2α4, 
INTRODUCTION
The c-Jun NH2-terminal kinase (JNK) signaling pathway represents one subgroup of MAP kinases. This pathway is primarily activated by cytokines and exposure to environmental stress, and it participates in many physiological functions (1, 2) . The JNK protein kinases are encoded by three genes, JNK1 (also known as MAPK8), JNK2 (MAPK9) and JNK3 (MAPK10), and their different physiological roles have been suggested (1) (2) (3) (4) . So far, at least 10 different JNK isoforms from the three JNK genes have been reported (5) , and many of their physiological substrates have been identified, such as ELK1, c-JUN, p53 and ATF2 (4, 6) . Among four known JNK2 transcript variants, α and β isoforms are distinguished by the alternate selection between two middle exons, whereas the alternate splicing at the C terminus leads to isoforms of 46 kDa (JNK2α1 and JNK2β1) and 54 kDa (JNK2α2 and JNK2β2). In fact, both splicing sites are present in all three JNK genes to create the p46/p54 or α/β JNK isoforms. These transcript variants show different substrate-binding (5, 6) and self-or substrate-phosphorylation activities (7) . Furthermore, different JNK2 transcript variants are differentially expressed (8) .
Alternative splicing, alternative transcription start, alternative cleavage and polyadenylation (APA) are the common mechanisms of adding complexity to transcripts and proteins in eukaryotic organisms (9, 10) . Our previous study suggests that single-block intronic EST with a polyadenylation site is the 3'-end exon site, potentially generating novel human transcript variants (11) . Therefore, 3'-end exon sites represent an effective way to discover novel transcripts in the human genome. Although we only confirmed one novel JNK2 transcript variant (11) , the integrated data suggest other potential JNK2 isoforms. As an extended effort, here we successfully cloned another four novel JNK2 transcript variants. Moreover, we showed that the JNK2 isoforms had different activities on AP-1 stimulation and substrate phosphorylation when they were over-expressed in mammalian cells.
RESULTS

Cloning and characterization of five novel human JNK2 transcript variants
As suggested in our previous study (11), we successfully cloned four novel JNK2 transcripts from mixed human tissue cDNA. Since several JNK2 isoforms have been reported (5), these novel transcript variants are designated as JNK2α3, JNK2α4, JNK2β3, JNK2γ1 and JNK2γ2, respectively. Among them, JNK2γ1 has been described in the previous report (11) . These transcript variants can be distinguished according to the exon combination: JNK2α3 and JNK2α4 contain an independent α exon; JNK2β3 contains an independent β exon; JNK2γ1 and JNK2γ2 contain novel 3'-end exons but not an in-http://bmbreports.org BMB reports Fig. 1 . The genomic structure and protein sequence alignment of human JNK2 isoforms. (A) The genomic structure of human JNK2 isoforms. Exons in black are numbered 1 to 13 at the top, while the extended exons or hidden exons are shown in grey. The translation start (ATG, all from the exon 2) and stop codons (TAA, TAG and TGA) are shown. For JNK2α1/2 or JNK2β1/2, the alternate 3' splice sites ('AG's in uppercase) result in isoform 1 from the second site and isoform 2 from the first site, respectively. (B) The protein sequence alignment of JNK2 isoforms. All sequences are presented in single letter code. Sequences in grey indicate the same or similar amino acid residues among JNK2 isoforms. Missing residues are illustrated with a dash. The α (bold) and β (italic) regions as well as the dual phosphorylation sites (Thrl83, Tyrl85), which mediate the JNK2 activation, in the tripeptide motif (Thr-Pro-Tyr) are shown. Kinase sub-domains (I-XI) are indicated (5) . The nucleotide sequences of novel JNK2 transcripts have been submitted to GenBank with the accession numbers HM036707 (JNK2α3), HM036708 (JNK2β3), EU927388 (JNK2γ1) and HM036706 (JNK2γ2). The four known reference protein sequences are derived from NP_620707 (JNK2α1), NP_002743 (JNK2α2), NP_620708 (JNK2β1) and NP_62 0709 (JNK2β2), while the others are the protein sequences deduced from the corresponding nucleotide sequences.
dependent α-or β exon. As shown in Fig. 1A , human JNK2 gene contains 13 exons, and exon 8 (α exon) encodes the α-region in the protein product, while exon 7 (β exon) encodes the β-region. For JNK2α1/2 and JNK2β1/2, an alternative 3' acceptor site in the final exon determines whether the transcript encodes JNK2α1/β1 (the second 3' acceptor site) or JNK2α2/β2 (the first 3' acceptor site). JNK2α3 contains exon 8 but lacks exon 7, while JNK2β3 is the exact opposite. Both JNK2α3 and JNK2β3 have an extension in exon 12 as the terminal exon. An additional novel exon is found between exon 2 and exon 3 of JNK2α4, and the resulting transcript contains a premature translation termination codon (PTC). Therefore, JNK2α4 is probably a potential substrate of nonsense-mediated mRNA decay (NMD), which selectively degrades mRNA containing PTC (12) . Both JNK2γ1 and JNK2γ2 contain an extended exon 8 as the terminal exon, and they lack exon 7. However, JNK2γ2 contains a small additional novel exon (66 nt) between exon 7 and exon 8 of JNK2 gene, and this small exon results in a PTC in JNK2γ2, making it a possible NMD substrate. All these five JNK2 variants comply with the GT/AG rule of RNA splicing, and they are not incompletely processed mRNA. Using PCR, we amplified all five JNK2 transcripts with the same outer and inner upstream primers. Meanwhile, specific downstream primers locating in the extended exon 8 or exon 12 were designed to amplify JNK2γ1/2 or JNK2α3/β3/α4, respectively. We cloned PCR products into a pGEM-T easy vector and sequenced them. The sequencing data demonstrated that among those recombinant clones derived from JNK2γ1/2 PCR products, most clones represented JNK2γ1, while only three clones were JNK2γ2. Furthermore, most of those clones from JNK2α3/β3/α4 PCR products represented JNK2α3 and JNK2α4, but we only obtained two JNK2β3 clones. These indicate that JNK2 transcript variants are differentially expressed at the RNA level.
Through searching human EST database, we found that both http://bmbreports.org the extended exon 8 and 12 were supported by multiple-block ESTs, such as AL525991 and AU124634. This result confirms the existence of the novel JNK2 transcript variants in human tissues or cells. Consistently, Kallunki et al. showed that multiple JNK2 transcripts with various sizes exist in human cell lines using northern blot analysis (6) . Fig. 1A and 1B show the analysis on the deduced protein products encoded by these JNK2 variants. Both JNK2α3 and JNK2β3 contain a complete kinase domain, whereas the kinase domains of JNK2γ1, JNK2γ2 and JNK2α4 are disrupted. Both JNK2α3 and JNK2β3 contain 378 amino acid residues, and JNK2γ1 contains 242 residues. Compared with JNK2α1 and JNK2β1, the five amino acids at the carboxyl terminal (AQMQQ) are replaced by a glycine (G) in JNK2α3 and JNK2β3, respectively (Fig. 1B) . This finding suggests that JNK2α1/ 3 or JNK2β1/3 cannot be easily distinguished from their relative molecular weights.
Expression profile analysis of the JNK2 transcript variants
We further examined the expression profile of the five JNK2 transcripts. Since JNK2γ2 was lowly expressed and it does not encode a protein product, we did not examine its expression based on the exclusive 66-nt exon. Fig. 2 shows that JNK2γ1, JNK2α3 and JNK2α4 were widely expressed in all surveyed cell lines, respectively ( Fig. 2A) . In A549 cells (Lane 5, 2nd panel), the weak band resulted from a badly loading sample. However, both JNK2α3 and JNK2α4 were actually expressed in A549 cells during re-electrophoresis (data not shown). Moreover, JNK2γ1 was also widely expressed in human tissues (2nd panel in Fig. 2B ), whereas JNK2α3 was highly expressed in human heart and placenta tissues (1st panel in Fig.  2B ). Since JNK2α4 is likely to be a NMD target, we did not investigate its expression in human tissues. Unexpectedly, we did not detect JNK2β3 in none of the cell lines or the tissues using specific primers (data not shown). We modified the PCR conditions and re-designed the downstream primers in the exon 7. However, we still did not detect any target bands in gel electrophoresis. Therefore, JNK2β3 should be very lowly expressed under the surveyed condition. For JNK2α3 and JNK2α4, their PCR products from the first-round amplification showed detectable bands during the nested-PCR experiments (data not shown), suggesting that they are highly expressed.
JNK2 isoforms show different AP-1 and substrate activities
In order to further investigate the function of the five JNK2 isoforms, we examined their expression in mammalian cells. Fig.  3A shows that both JNK2α3 and JNK2β3 encode the same-size protein with a relative molecular mass of 46 kDa. They could be highly and stably expressed, suggesting that they are physiologically functional protein-encoding transcripts. Fig. 3A shows that JNK2γ1 and JNK2γ2 could not be detected by anti-SAPK/JNK antibody. No target protein bands could be visualized even when the explosion time was extended with the enhanced chemiluminescence detection kit (Invitrogen). Similarly, JNK2α4 could not be recognized by anti-SAPK/JNK antibody (data not shown). However, JNK2γ1, rather than JNK2γ2, was detected using an anti-Myc antibody (although two weak bands appeared) (Fig. 3B) . The deduced molecular mass of JNK2γ1 is 27 kDa, so it remains unclear whether the lower band is the degraded product or the translated protein from another start codon ATG. JNK2γ2 may be a candidate of NMD, although the distance between PTC and the last exon-exon junction is shorter than 50 nt.
Using cis-and trans-dual-luciferase reporter assay systems, we examined the activities on the cis-AP-1, trans-c-JUN and ELK1 luciferase reporters by over-expressing the JNK2 isoforms in 293T cells. As shown in Fig. 3C , the JNK2 isoforms demonstrated distinct activities with cis-AP-1 reporter as well as trans-c-JUN and ELK1 reporters. In general, JNK2 isoforms with an α region demonstrated higher activities than those with a β region, which has been suggested in previous studies (6, 7) . In terms of promoting cis-AP-1 activities, the JNK2 alpha isoforms were much more efficient than the JNK2 beta and gamma isoforms, and moreover, JNK2α3 had the strongest effect. Meanwhile, JNK2α1 and JNK2α2 showed the highest activation of c-JUN and ELK1, respectively. There was no significant difference on cis-AP-1, and trans-c-JUN and ELK1 activities between JNK2β1 and JNK2β3. JNK2γ2 was the weakest isoform, and it could not efficiently promote these reporter activities. The function of JNK2γ1 was greatly influenced, however, it could not function as a dominant negative isoform in that it did not inhibit the cis-AP-1, trans-c-JUN and ELK1 activities when co-expressed with the known isoform JNK2α2 or JNK2β1 (Fig. 3C) . We also detected the AP-1 activity stimulated by JNK2 alpha and beta isoforms in HeLa cells, although the rela-http://bmbreports.org BMB reports , and auto-phosphorylation at Thr183/Tyr185 (E, F). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibody was used to confirm the equal amount of loading protein (E, F).
tive fold change was weaker than that in 293T cells (data not shown). JNK2α3 and JNK2β3 contain an intact kinase domain, so they represent the full-length, non-truncated isoforms. We further examined the phosphorylation of endogenous substrates (c-JUN and ATF2) stimulated by the over-expressed two transcripts in 293T cells. Fig. 3D shows that compared with the negative control, both JNK2α3 and JNK2β3 increased the phosphorylation level of c-JUN, though the former demonstrated a relative higher potential. Similarly, both of them could stimulate the phosphorylation of ATF2, and JNK2β3 demonstrated the same potential as JNK2 alpha isoforms (Fig. 3D) . Our results are consistent with the previous observation that JNK2 beta isoforms are more efficient than JNK2 alpha isoforms in binding to ATF2, while JNK2 alpha isoforms are more efficient than JNK2 beta isoforms in binding to c-JUN (5). We did not find that JNK2γ1 was capable of strongly promoting the phosphorylation of the two substrates (data not shown). These results suggest that the JNK2 isoforms have different activities on substrates in vivo or in vitro.
JNK2 isoforms show different autophosphorylation
Previous studies have revealed that JNK2 can be autoactivated, even without upstream kinase or extracellular stimuli (7) . Since the phosphorylation of Thr183/Tyr185 in the kinase domain directly reflects the active status of JNK2 itself (13, 14) , we investigated this substrate phosphorylation in JNK2 alpha and beta isoforms when they were over-expressed in 293T cells. Both JNK2α3 and JNK2β3 had strong autophosphorylation at Thr183/Tyr185, but JNK2α1 showed a higher phosphorylation level than JNK2β1 (Fig. 3E and 3F) , which might explain a higher phosphorylation efficiency with the substrate c-JUN by JNK2α1 (Fig. 3G) . There are only five amino acids (AQMQQ) different at the carboxyl terminal between JNK2α1 and JNK2β1 or JNK2α3 and JNK2β3, suggesting that these terminal amino acids are greatly associated with phosphorylation status of JNK2 beta isoforms but not JNK2 alpha isoforms. Cui et al. reported that carboxyl region can regulate the autophosphorylation of JNK isoforms (15) , and the underlying mechanism remains to be explored.
JNK2α3 and JNK2β3 can promote cell proliferation
In order to evaluate the effect of JNK2 isoforms on cell proliferation, we transiently transfected 293T cells with JNK2 isoform recombinant plasmids in pCMV-SPORT6 vector and preformed CCK8 assay. As shown in Fig. 4 , compared with the blank vector pCMV-SPORT6, the cells transfected with JNK2α3, JNK2β3 and JNK2α2 (positive control) demonstrated an increased cell proliferation during a three-day period. This result suggests that both JNK2α3 and JNK2β3 can promote cell proliferation, consistent with a previous report that JNK2 is a positive regulator of cell proliferation (16) . Moreover, JNK2γ1 and JNK2γ2 did not apparently increase the cell proliferation, nor did JNK2γ1 inhibit the proliferation potency of JNK2α2, JNK2α3 and JNK2β3 (data not shown).
DISCUSSION
In the present study, we cloned and identified five novel JNK2 http://bmbreports.org transcript variants according to single-block intronic ESTs with a polyadenylation site (11) . They are all expressed at the RNA level. At the protein level, most monoclonal JNK2 antibodies in the market only recognize p54 and p46 JNK2 isoforms, but a few polyclonal JNK2 antibodies can recognize more endogenous JNK2 isoforms, suggesting the existence of other JNK2 isoforms. For example, in human cells, endogenous protein bands with various sizes can be detected by many Abcam JNK2 antibodies including ab69648 and ab57717. Because the monoclonal anti-SAPK/JNK antibody we used cannot recognize JNK2γ1, we could not detect endogenous JNK γ isoforms at the protein level.
The α and β regions determine the binding activities of JNK2 substrates (5, 6) , and the α region is also important for JNK2 in autophosphorylation (15) and dimerization (17) . Consistently with this view, JNK2α3 showed higher cis-AP-1 and different substrate activities compared with JNK2β3, further suggesting that the α and β regions are directly involved in the divergent function of various JNK2 isoforms. Though JNK2γ1 contains a complete α region, it has a disrupted kinase domain and the function is greatly disabled. But the similar transcriptional activity to JNK2 β isoforms (Fig. 3C) revealed that the kinase activity of JNK2γ1 should not be completely destroyed.
Since both JNK2 alpha and beta isoforms can promote the phosphorylation of many substrates, another interesting issue is why they show such a large difference on cis-AP-1 activities. AP-1 is a homo-or hetero-dimer. In mammalian cells, FOS and JUN are the main components to form AP-1 complexes that recognize the DNA response element known as the TPA-responsive elements (TREs, consensus sequence 5'-TGAG/CTCA-3') (18, 19) . Generally speaking, different dimer combinations preferentially recognize different DNA sequence elements such as the cAMP response element (CRE, consensus sequence 5'-TGACGTCA-3'), the MAF-recognition elements (MAREs) and the antioxidant-response elements (AREs) in the promoters and enhancers of target genes (18, 19) . The observed difference suggests that various JNK2 isoforms control different target genes by interacting with distinct preferential DNA binding elements. However, more efforts are required to investigate whether the novel JNK2 isoforms, especially the full-length JNK2α3 and JNK2β3, play important roles in physiological or pathological processes.
MATERIALS AND METHODS
Cloning and sub-cloning of novel human JNK2 transcript variants
We cloned uncharacterized transcript variants using the RT-PCR based strategy as previously described (11) . We designed the outer forward primer (F1, 5'-ctgaaacttgcccacccttcg-3'), the inner forward primer (F2, 5'-atattgcaggacgctgcatcatg-3'), the outer reverse primers (R1, 5'-cccaaggatggagaccaatttaaac-3'; R3, 5'-gttgaatagggaaagaaaaatatcatac-3') and the inner reverse primers (R2, 5'-tgaaaaagggaagatgtgaagaacc-3'; R4, 5'-aatcaattaaagcaatcactaacctg-3'), respectively. The reverse primers R1 and R2 were for JNK2γ1 or JNK2γ2, while the primers R3 and R4 were for JNK2α3, JNK2α4 or JNK2β3. The cDNA template, PCR conditions and sequence analysis were as previously described (11) . The PCR products were recovered, cloned into a pGEM-T easy vector (Promega, USA) and varified by sequencing. Then, the open reading frame (ORF) of JNK2 transcripts was further subcloned into the mammalian expression vector pCMV-SPORT6 (Invitrogen, USA) at EcoRI and NotI sites. For JNK2γ1 and JNK2γ2 constructs, a fused Myc/His tag was also introduced. JNK2α1 and JNK2β1 constructs in the vector pCMV-SPORT6 were from SinoGenoMax Co., Ltd (China). JNK2α2 in pCMV-SPORT6 vector was obtained from mammalian gene collection (MGC) clone (BC032539) and used as a positive control.
Reverse transcription-PCR (RT-PCR)
Human tissue cDNA from colon, testis, heart and placenta was purchased from SinoGenoMax Co., Ltd., China, and the nested-PCR was performed. To assess the JNK2γ1 expression, the outer forward primer F1 and reverse primer R1 were used, and the inner forward and reverse primers were 5'-tcagactgcaccctgaagatcct-3' and 5'-tggattttacgactttgtcctcgt-3', respectively. To assess the expression of JNK2α3 and JNK2β3, the outer forward primer F1 and reverse primer R3 were used, the inner forward primers were 5'-agagctggtgaaaggttgtgtgat-3' (JNK2α3) and 5'-aatggtcctccataaagtcctgttc-3' (JNK2β3), and the common reverse primer was R4. The inner primers F2 and R4 were also used to assess the JNK2α4 expression with the first PCR products from primers F1 and R3. The Touchdown-PCR method and PCR conditions were as previously described (11) .
For cell lines, RNA was extracted with TRIzol reagent (Invitrogen), and PCR was performed with the ThermoSCRIPT RT-PCR System (Invitrogen) according to the manufacturer's protocol.
Cell culture, transient transfection and dual-luciferase reporter assay
293T or HeLa cells were maintained in DMEM (HyClone) supplemented with 10% fetal bovine serum and were incubated in a 5% CO2 incubator at 37 o C. Dual-luciferase reporter assay was described previously (20) . For the cis-luciferase reporter gene assays, a total of 144 ng plasmid DNA per well were used, including 100 ng of JNK2 isoform plasmid or the blank vector pCMV-SPORT6 (as vector control), 40 ng pAP1-Luc (Clontech), and 4 ng pRL-TK (Promega) used as an internal control. For the trans-luciferase reporter assay, the only modification compared with the cis-luciferase reporter assay was the plasmids (total 148 ng) used for co-transfection: each well contained 4 ng of pFA2-cJun, or pFA2-ELK1 (PathDetect, Stratagene), 40 ng of pFR-Luc (PathDetect, Stratagene), 100 ng of JNK2 isoform plasmid or pCMV-SPORT6, and 4 ng pRL-TK. For co-expression among JNK2 isoforms, each JNK2 isoform plasmid was equivalently used but the total plasmid amount kept unchanged.
Cell proliferation assay
In order to measure cell proliferation, cell counting kit-8 assay (CCK8, Dojindo, Kumamoto, Japan) was preformed in 293T cells. The pCMV-SPORT6-JNK2 isoform constructs were transfected or co-transfected, and the blank pCMV-SPORT6 vector was used as the negative control. Subsequently, the transfected 293T cells (1,000 cells/well) were seeded in 96-well plate and tested by CCK8 kit according to the manufacturer's protocol. The measurement was preformed at 450 nm during a threeday culture period with a 12-hour interval.
Western blot analysis
Western blot was preformed as previously described (20) . In our study, antibodies against SAPK/JNK, c-Jun and ATF2 were used. In order to detect the phosphorylated proteins, anti-phospho-SAPK/JNK (Thr183/Tyr185), anti-phospho-c-Jun (Ser63) and anti-phospho-ATF2 (Thr71) antibodies were also purchased from Cell Signaling Company, Ltd.
